Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...
Bemdaneprocel is administered by surgical transplantation into a part of the brain known as the putamen, in the hope of ...
Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's ...
University of Arizona researchers revealed that dyskinesia in Parkinson’s patients stems from a disconnect in the motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback